Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endotoxin-induced immune response in the lower respiratory tract in smokers with and without chronic bronchitis and/or COPD
2010-023681-45Phase 2Terminated
- Sponsor
- Sahlgrenska University Hospital
- Start
- Feb 2011
- Countries
- 1
01
Overview
Phase 2, open-label trial of lipopolysaccharide endotoxin in chronic obstructive pulmonary disease (COPD), chronic bronchitis (CB) and airway inflammation (2 arms), sponsored by Sahlgrenska University Hospital. Primary endpoint: Cell content of the BAL fluid, changes in inflammatory cells and mediators in airways. Started Feb 2011; status: terminated.
02
Drugs
lipopolysaccharide endotoxin
03
Conditions
chronic obstructive pulmonary disease (COPD)chronic bronchitis (CB)airway inflammation
Beyond the preview
Go deeper on 2010-023681-45.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023681-45.